VANCOMYCIN PHARMACOKINETICS IN A PATIENT POPULATION - EFFECT OF AGE, GENDER, AND BODY-WEIGHT

被引:121
作者
DUCHARME, MP
SLAUGHTER, RL
EDWARDS, DJ
机构
[1] WAYNE STATE UNIV,COLL PHARM & ALLIED HLTH PROFESS,DEPT PHARM PRACTICE,DETROIT,MI 48202
[2] DETROIT RECEIVING HOSP & UNIV HLTH CTR,DEPT PHARM SERV,DETROIT,MI
关键词
VANCOMYCIN; PHARMACOKINETICS; AGE; GENDER; OBESITY;
D O I
10.1097/00007691-199410000-00013
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
The effects of age, gender, and body weight on the pharmacokinetics of vancomycin were examined using data collected as part of routine therapeutic drug monitoring in patients. One thousand eighty-five sets of steady-state peak and trough serum concentrations obtained from 704 different patients were used to calculate elimination rate constant (k), volume of distribution (V), and clearance (Cl) using a one-compartment model. The median half-life of vancomycin was 6.5 h. Clearance was significantly correlated with creatinine clearance as estimated using the Cockcroft-Gault equation [Cl = 0.771 (Cl-cr) + 18.9; r = 0.63]. V averaged 0.69 L/kg ideal body weight (IBW) with increased values in females, patients over age 60, and obese patients. V ranged from 0.58 L/kg IBW in normal weight males under age 40 to 1.17 L/kg IBW in obese females over age 60. V was not different in underweight patients and those of normal weight (43.8 vs. 44.4 L). Regression analysis indicated that V was more predictable in women than in men and that vancomycin distributed into excess body weight (EBW) to a greater extent in women. However, the correlation coefficients from multiple regression analysis of V with IBW, EBW, and age did not exceed 0.60, and the high root mean square error values of 11-15 L suggest considerable variability in V is not accounted for by these factors alone. Despite these limitations, dosing of vancomycin may be improved by adjusting initial estimates of V for patient age, gender, and obesity.
引用
收藏
页码:513 / 518
页数:6
相关论文
共 16 条
[1]   VANCOMYCIN PROTEIN-BINDING IN PATIENTS WITH INFECTIONS CAUSED BY STAPHYLOCOCCUS-AUREUS [J].
ALBRECHT, LM ;
RYBAK, MJ ;
WARBASSE, LH ;
EDWARDS, DJ .
DICP-THE ANNALS OF PHARMACOTHERAPY, 1991, 25 (7-8) :713-715
[2]   USING CLINICAL-DATA TO DETERMINE VANCOMYCIN DOSING PARAMETERS [J].
BIRT, JK ;
CHANDLER, MHH .
THERAPEUTIC DRUG MONITORING, 1990, 12 (02) :206-209
[3]   VANCOMYCIN PHARMACOKINETICS IN NORMAL AND MORBIDLY OBESE SUBJECTS [J].
BLOUIN, RA ;
BAUER, LA ;
MILLER, DD ;
RECORD, KE ;
GRIFFEN, WO .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1982, 21 (04) :575-580
[4]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[5]   VANCOMYCIN DISPOSITION - THE IMPORTANCE OF AGE [J].
CUTLER, NR ;
NARANG, PK ;
LESKO, LJ ;
NINOS, M ;
POWER, M .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1984, 36 (06) :803-810
[6]   ESTIMATING CREATININE CLEARANCE IN MORBIDLY OBESE PATIENTS [J].
DIONNE, RE ;
BAUER, LA ;
GIBSON, GA ;
GRIFFEN, WO ;
BLOUIN, RA .
AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1981, 38 (06) :841-844
[7]   VANCOMYCIN PHARMACOKINETICS, RENAL HANDLING, AND NONRENAL CLEARANCES IN NORMAL HUMAN-SUBJECTS [J].
GOLPER, TA ;
NOONAN, HM ;
ELZINGA, L ;
GILBERT, D ;
BRUMMETT, R ;
ANDERSON, JL ;
BENNETT, WM .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 43 (05) :565-570
[8]   COMPARISON OF VANCOMYCIN PHARMACOKINETICS IN HOSPITALIZED ELDERLY AND YOUNG-PATIENTS USING A BAYESIAN FORECASTER [J].
GUAY, DRP ;
VANCEBRYAN, K ;
GILLILAND, S ;
RODVOLD, K ;
ROTSCHAFER, J .
JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 33 (10) :918-922
[9]   COMPARISON OF STEADY-STATE PHARMACOKINETICS OF 2 DOSAGE REGIMENS OF VANCOMYCIN IN NORMAL VOLUNTEERS [J].
HEALY, DP ;
POLK, RE ;
GARSON, ML ;
ROCK, DT ;
COMSTOCK, TJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (03) :393-397
[10]   PHARMACOKINETICS OF VANCOMYCIN IN PATIENTS WITH VARIOUS DEGREES OF RENAL-FUNCTION [J].
MATZKE, GR ;
MCGORY, RW ;
HALSTENSON, CE ;
KEANE, WF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1984, 25 (04) :433-437